Biotech Values

[DewDiligence]

Barr’s date-certain launches:

In addition to its rich portfolio of ANDA’s and Paragraph-IV challenges, BRL has several date-certain launches of major generic drugs based on prior patent settlements. The following table shows nine such drugs, of which six have yet to be launched:




Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”